It’s the first FDA approval for a pain medication in 25 years. How does the drug work, and who is it for?

Among 196 doctors who prescribed clozapine, 64% said the positive aspects of the REMS certification process outweighed the ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

KODATEF is not approved for use in the U.S. Demand for ARAKODA has been steadily growing in recent months as awareness and use of the product has expanded across the U.S. The Company is taking the ...

In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now ...

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...

We recently published a list of Jim Cramer Tells Viewers To Not Trust Billionaires & Discusses These 11 Stocks.

Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...

Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ...